Virtual Library

 x 
My Library Virtual Library FAQ

Start Your Search

C. Locher



Author of

  • +

    P3.02a - Poster Session with Presenters Present (ID 470)

    • Event: WCLC 2016
    • Type: Poster Presenters Present
    • Track: Advanced NSCLC
    • Presentations: 1
    • +

      P3.02a-004 - NSCLC Patients Harboring ALK Translocation: Clinical Characteristics and Management in Real World Setting. EXPLORE GFPC 02-14 (ID 5043)

      14:30 - 14:30  |  Author(s): C. Locher

      • Abstract

      Background:
      ALK (Anaplastic Lymphoma Kinase) translocation is a rare oncogenic driver in NSCLC (Non Small Cell Lung Cancer) (3 to 5%) and few data are published on the management of these patients outside patients included in clinical trial. objective:to investigate clinical characteristics and management of these patients in real world setting.

      Methods:
      inclusion of patients with a diagnosis of NSCLC harboring ALK translocations between January 2012 and December 2014, collection of demographic and clinical characteristics, risk factors, Progression free survival (PFS), Overall Survival (OS), mode of progression and therapeutic management

      Results:
      132 patients recruited in 31 centers: 67(51%) men; age: 60.1 ± 14,5 years; PS 0/1 at diagnosis: 89%; non smokers:79%, adenocarcinoma: 93%; Stage at diagnosis 4/3/2-1:74%/19%/7%: co-mutations EGFR n=2, BRAF n=2, KRAS = 1, HER2 = 1. Outcomes of stage IV (n=97): first line treatment: chemotherapy: 75%, Best supportive care (BSC): 1 %, anti ALK: 24 %; response rate, disease control rate (DCR) and PFS to first line treatment: 42 %,64% and 7.5 months (CI 5.9 ;9.5), second line treatment (n=60): chemotherapy: 25%, anti BRAF 72%, BSC 3 %; response rate, DCR and PFS to second line treatment: 43.4%,70% and 4,7 months (CI 4.0; 8.1); 2 years-OS: 56.7% (CI 45.5 ;70.4), mediane OS was not reach.

      Conclusion:
      In this real world analysis, the majority of NSCLC patients with ALK translocation were non smokers,adenocarcinoma and appears to have a better survival to NSCLC pts without oncogenic driver. Clinical trial information: Supported by an academic grant from Lilly, Astra Zeneca, boehringer ingelheim